22Feb 2024
Clinicians Reach Consensus on Ataluren Use in Duchenne Muscular Dystrophy Treatment

Clinicians Reach Consensus on Ataluren Use in Duchenne Muscular Dystrophy Treatment

A study assessing clinician consensus on ataluren usage in nonsense mutation Duchenne muscular dystrophy (nmDMD) patients reveals strong agreement. Conducted via modified Delphi methodology, involving 1:1 interviews and consensus surveys among healthcare professionals, the research found consensus (>66%) on 41 out of 42 statements. Findings suggest early initiation of ataluren to delay disease progression and maintain ambulation. Results indicate significant alignment among clinicians, emphasizing the drug's potential in nmDMD treatment.

  • #neurology

Like

Save

Share